Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data

Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data A severe complication of the treatment of pediatric cancers is the development of an invasive fungal infection (IFI). The data to support antifungal prophylaxis in pediatric oncology patients derive primarily from adult patients, and thus the optimal agent to utilize is not clear. Fluconazole has been a standard option, but agents with antimold activity are now available, each with limitations. Pediatric dosing for voriconazole and posaconazole is uncertain and multiple drug interactions exist. The echinocandins are well‐tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies. Pediatr Blood Cancer 2012; 59: 21–26. © 2011 Wiley Periodicals, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatric Blood & Cancer Wiley

Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data

Loading next page...
 
/lp/wiley/antifungal-prophylaxis-in-pediatric-hematology-oncology-new-choices-DfFqz1LHFz

References (61)

Publisher
Wiley
Copyright
Copyright © 2011 Wiley Periodicals, Inc.
ISSN
1545-5009
eISSN
1545-5017
DOI
10.1002/pbc.23415
pmid
22102607
Publisher site
See Article on Publisher Site

Abstract

A severe complication of the treatment of pediatric cancers is the development of an invasive fungal infection (IFI). The data to support antifungal prophylaxis in pediatric oncology patients derive primarily from adult patients, and thus the optimal agent to utilize is not clear. Fluconazole has been a standard option, but agents with antimold activity are now available, each with limitations. Pediatric dosing for voriconazole and posaconazole is uncertain and multiple drug interactions exist. The echinocandins are well‐tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies. Pediatr Blood Cancer 2012; 59: 21–26. © 2011 Wiley Periodicals, Inc.

Journal

Pediatric Blood & CancerWiley

Published: Jul 15, 2012

There are no references for this article.